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ABSTRACT
Background: AIDS (acquired immunodeficiency syndrome) related cholangiopathy 
results from the inflammation of biliary tree and gall bladder. It is an uncommon 
manifestation of advanced HIV/AIDS that was associated with poor prognosis prior 
to the anti-retroviral therapy era. It commonly presents with biliary tree pain. Jaundice 
is uncommon and other symptoms include fever and vague abdominal pains. Patients 
have low CD4+ cell counts of between 50-200 cells/µl. It is rarely fatal but presents 
with marked epigastric pain, which affects the quality of life. Management is mainly 
conservative or surgical in selected cases.
Objective: To describe AIDS-related cholangiopathy and the associated ultrasound 
features, immunological and biochemical markers in a cohort of HIV positive 
patients.
Design: Longitudinal, consecutive entry, prospective study.
Setting: Kisumu District Hospital medical and surgical wards, Mater and Nairobi west 
hospitals between January 2001 and May 2007.
Subjects: Seventy nine patients with cholangiopathy/ cholecystitis were included in 
the study.
Intervention: Antibiotics, analgesics, intravenous fluids/or surgery was offered to the 
patients. 
Main outcome measures: Clinical, biochemical and ultrasound features, management 
(surgical or conservative), CD4+ cell counts.
Results:  One hundred and two (42 males and 60 females) patients were screened. Twenty 
three (ten males and 13 females) patients were excluded. Seventy nine (32 males and 
47 females) patients were included in the study. Their mean age was 38.8 ± 11.5 (17-70) 
years. The mean CD4+ cell count and white cell count were 122.4 ± 85.8 cells/µl (3.0-
380) and 12.8 ± 4.5 X103/µl respectively. Mean ALT, AST and alkaline phosphatase were 
413.4 ± 126.4 IU/L (range 160-800), 340.5 ± 113.3 IU/L (range 92-562) and 678.8 ± 535.9 
IU/L (range 55-2790). Ultrasound showed varied features: Isolated dilated intrahepatic 
bile ducts in eight patients, enlarged gall bladder with thickened wall (cholecystitis) 
in thirty one patients, thickened common bile duct wall and cholecytitis and dilated 
intrahepatic and common bile duct, ten each, eleven had cholecystitis and gallstones 
and nine had normal ultrasound scan. The co-morbidities include; PTB in four patients, 
six had pneumocystis jiroveci pneumonia, two had cryptococcus meningitis, three had 
cryptosporidium/ microsporidium, ten had oral candidiasis, four had Kaposi’s Sarcoma, 
seven had herpes zoster virus, one had broncho-pneumonia, ten had diarrhoea and 
thirty two had no infections. Seven patients had cholecystectomy done successfully 
and 72 patients were managed conservatively.
Conclusion: AIDS- related cholangiopathy has diffuse biliary tree abnormalities. The 
patients had very low mean CD4+ cell counts signifying severe immunosuppression. 
The co-morbidities were observed to occur at very low CD4+ cell counts. Management 
is both conservative and surgical.
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INTrODUCTION
Biliary duct abnormality in patients with HIV/
AIDS (AIDS cholangiopathy/cholangitis) was first 
described in 1988 by Mangulis et al (1).  It results 
from inflammation of gall bladder and biliary tree. 
It is an uncommon manifestation of advanced HIV/
AIDS and commonly presents with billiary tree pain. 
Jaundice is rare and cholangiopathy occurs at very 
low CD4+ cell counts of 50-200 cells/µl (1). There 
can be a spectrum of involvement ranging from 
acute acalculous cholecystitis to papillary stenosis 
with bile duct obstruction or a diffuse disease with 
sclerosing cholangitis-like picture with gall bladder 
involvement (1, 2).  This was further characterised 
endoscopically by endoscopic retrograde cholangio-
pancreatography (ERCP) in the late 1980’s (2). AIDS 
related cholangiopathy/cholangitis has been reported 
in few series and reports. It causes a lot of morbidity 
due to the pain which reduces the quality of life of 
patients (3).
 The aetiology of AIDS cholangiopathy/
cholangitis remains unclear. The likely causes include 
opportunistic infections like cryptosporidium, 
cytomegalovirus (CMV) and microsporidium and 
rarely, Kaposi’s sarcoma (3).  AIDS cholangiopathy/
cholangitis is rarely fatal and other AIDS-related 
illnesses and progression of immunodeficiency are the 
usual causes of death for these patients (4–7).  AIDS 
cholangiopathy/cholangitis may present with less 
acute right upper quadrant pain, fever and nausea 
with cholestatic liver enzyme abnormalities. In 
acute acalculous cholecystitis, ultrasound, C-T Scan 
or MRI scan shows a thickened gall bladder wall in 
the absence of cholelithiasis.  In patients who are fit 
for anaesthesia, cholecystectomy is usually required 
and HIV/AIDS is not a reason to defer surgery 
(8–11).  Some of the patients can be asymptomatic 
and this makes the prevalence of this disease entity 
unknown (5). Indeed, the prevalence of HIV/AIDS 
cholangiopathy is poorly understood and data are 
scanty. 
 Longitudinal studies evaluating the prevalence 
of cholangitis/cholangiopathy or other hepato-biliary 
disorders in HIV/AIDS patients in sub-Saharan Africa 
is scanty hence the rationale of this study.
MATErIALS AND METHODS 
One hundred and two (42 males and 60 females) 
patients with cholecystitis/cholangitis were screened. 
These were patients who presented with marked 
right upper quadrant pain with or without jaundice. 
The patients included were HIV positive and had 
cholecystitis/cholangiopathy. The patients excluded 
had cholangitis/cholecystitis and were HIV negative 
or declined HIV testing. Twenty three patients were 
excluded ( 20 HIV negative, three declined HIV 
test). 
A total of 79 patients (32 males and 47 females) who 
were seen over a period of 50 months (January 2003 
– May 2007), were recruited into the study.  The study 
was conducted at Kisumu District Hospital (medical 
outpatient clinic, medical and surgical wards) and 
Nairobi Rheumatology Clinic and Mater Hospital. 
It included all the patients who were consecutively 
enrolled and met the inclusion criteria. The ethics 
and standards committee at the Kisumu District 
Hospital approved the study.  A signed, informed 
consent was obtained from each patient, and < 18 
year olds, signed by parent or guardian.  Some, 
nine, were patients with known HIV positive sero-
status and others (70),  were newly diagnosed and 
diagnostic counselling and testing (pre- and post-) 
was done and sustained.  The following information 
was obtained from each patient and their records: 
Socio-demographic data, abdominal ultrasound 
scan, eight millilitres of blood taken under aseptic 
condition from the cubital fossa. The patients were 
clinically examined for fever, jaundice, right upper 
quadrant pain and opportunistic infections and other 
co-morbidities by one of the authors (MDs).
 The eight millilitres of blood which was drawn 
from each patient was divided into two equal aliquots 
of four millilitres each.  Serum was separated from one 
aliquot soon after collection and used for serology for 
HIV (human immunodeficiency virus) and hepatitis B 
virus surface antigen (HBsAg) by ELISA test. The other 
four millilitres of whole blood was used for analysis 
of CD4+ cell count, complete blood count, liver 
function tests- alanine transaminase (ALT) , aspartate 
transaminase (AST) , and alkaline phosphatase (ALP). 
CD4+ cell count was done using the FACS (fluorescent 
activated cell sorter) flow cytometry count method. 
The FACS flow cytometry machine has a sensitivity 
of 1-2000 cells/µl. Complete blood count was done 
by coulter counter machine.
 ALT and AST analysis was done using the 
technicon RA 1000 machine (Technicon RA systems 
No. sm – 0034 D91 and No. sm 4 – 0137, D 91, 
1996) and ALP was analysed using  reverse passive 
haemagglutination test (R.P.H.A) method. 
 HIV test was done using ELISA method with 
a sensitivity and specificity of 99.9% and 98.9% 
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respectively; HBsAg was analysed using Microelisa 
system, hepanostika (HBsAg Uni-FormII).
 The presence of cholecystitis/ cholangiopathy 
was defined as elevated AST, ALT and/or ALP and 
clinical presentation of right upper quadrant pain/
tenderness, jaundice, fever and ultrasound description 
of cholecystitis/ biliary tree abnormality.
 The raw data were cleaned, entered into a 
computer and analysed using SPSS package.  The 
results were expressed as mean ± SD, tables and bar 
charts.
Intervention: All the patients in the study were 
appropriately managed conservatively as inpatients 
on intravenous antibiotics/analgesics fluids or 
surgery (Cholecystectomy).  Seven patients with 
severe pruritus and sepsis had cholecystectomy 
done, given antibiotics and did well post-operatively 
and recovered.  Highly active anti-retroviral therapy 
(HAART) was given to the patients who consented 
and could afford. The study was carried out during 
the period when the national ART access programme 
by Ministry of health had not been rolled out. 
rESULTS 
The results were expressed as mean ± SD, figures, 
tables and bar charts.  
 Seventy nine (32 males and 47 females) were 
included in the study. The mean age was 38.8 ± 11.5 
years (17-70). All the 79 patients were HIV positive 
and had right upper quadrant tenderness, sixty nine 
were jaundiced and fifty had fever.
 The four major clinical signs were jaundice, 
fever, diarrhoea and right upper quadrant abdominal 
pain present in 40, 63.3, 8 and 90% of patients 
respectively.
The mean CD4+ cell count was 122.4 ± 85.8 cells/µl 
(range, 3.0-380). Abnormal liver functions tests were 
present in all the patients. The serum level of Alkaline 
phosphatase was most persistently elevated feature 
(95% of patients) with a mean elevation of 678.8 ± 
535.9 IU/L, (range 55-2790) (12xULN). 
 Serum AST and ALT was raised in 90 and 96% 
of patients respectively. Mean AST was 340.5 ± 113.3 
(92-562) IU/L (4-20XULN) and ALT was 413.4 ± 126.4 
(160-800) IU/L (3-13XULN). Mean white blood cell 
count was 12.8 ± 4.5 X103/ml (2.2-20.1 X103). Fifty 
patients had mean leucocytosis and neutrophilia of 
12.8 X 103/ml and 81.2 ± 3% respectively. Fifty four 
(68.4%) patients were able to afford, consented and 
were initiated on HAART.
 Thirty two (40.5%) patients had no co-infection 
or other morbidity and 47 (59.5%) patients had co-
infection, Table 3.
 Abdominal ultrasound features were varied and 
included: dilated intrahepatic and common bile duct 
(ten patients), isolated dilatation of intraheptic bile 
ducts (eight patients), enlarged gall bladder with 
thickened wall (cholecystitis) (thirty one patients), 
thickened common bile duct wall and cholecystitis 
ten, cholecystitis and gall stones in eleven patients and 
normal ultrasound scan in nine. Seven of the eleven 
patients with gallstones also had sepsis and severe 
pruritus and had cholecystectomy done. Seventy 
two (91.1%) patients had contracted or thickened 
gall bladder wall with sludge/abnormal biliary tree 
and were managed conservatively on antibiotics, iv 
fluids and analgesics as hospitalised patients. 
 However, nine patients (11%) had normal 
abdominal ultrasound scan and were diagnosed to 
have cholangiopathy/cholangitis by the presence 
of jaundice, diffuse abdominal pains and abnormal 
biochemical features.




Number of patients screened = 102
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completed the study
72 conservative



































December 2013 (Supplement) East african MEdical Journal    S29
Figure 2
Age and gender distribution of HIV patients who had cholecytitis
 
Table 2 
Laboratory Features of the 79 patients with HIV/AIDS and Cholangiopathy.
Feature Range Mean  ± SD
ALP ( IU/L) 55-2790 678.8  ± 535.9 
AST (5-40 IU/L) 92-562 340.5  ± 113.3 
ALT (5-37 IU/L) 160-800 413.4  ± 126.4
Bilirubin (1-17µmol/L)
CD4+ cell count (cells/ml) 3.0-380 122.4  ± 85.8 
White blood cell count 2.2-20.1 12.8  ± 4.5 X 103
Neutrophil (45-70%) 81.2  ± 3
ALP - Alkaline phosphatase
Ast - Aspartate transaminase
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Table 3
Baseline characteristics and CDC-staging of the 79 HIV positive patients with cholangiopathy/cholecystitis.
Parameter Value  
M:F ratio 42:60 (1:1.4)
Mean age (years) 38.8 ± 11.5 (17-70)
CD4+ cell count (cells/µl)
      Mean 122.4 ± 85.8 (3.0-380)
      > 500 1(1.3%)
      350-499 1(1.3%)
      200-349 11(13.9%)
      < 200 66(83.5%)
      *CDC clinical staging
      A 4(5.0)
      B 10(12.7%)
      C 65(82.3%)
      ALP (64-306 IU/L) 678.8 ±535.9 (55-2790)
      AST (5-40 IU/L) 340.5 ±113.3 (92-562)
      ALT (5-37 IU/L) 413.4 ± 126.4 (160-800)
      Bilirubin(1-17µmol/L)
      White blood cell count(4-10.3 X 103/µl) 12.8 ± 4.5 (2.2-20.1)
      Neutrophil count (40-70%) 81.2± 3
      Ultrasound features:
      Cholangitis/cholangiopathy 70
      Normal 9
*CDC-Centres for Disease Control. Source, Morb. Mort. Week. Rep. 42 (No. RR-17), Dec. 18.1992 (A-asymptomatic 
PGL, B-symptomatic, not A or C conditions, C-AIDS defining illness). ALP-alkaline phosphatese, ALT-alanine 
transaminase, AST-aspartate transaminase.   
Table 4
Opportunistic infections in the 79 patients with HIV and cholangiopathy/Cholecystitis.
No. of patients 0.Is 
4 PTB (pulmonary tuberculosis)
6 PJP (pneumocystis jiroveci pneumonia))
2 Cryptococcous  
3 Cryptosporidium/microsporidium  
10 Oral candidiasis 
4 Kaposi’s Sarcoma 
7 Herpes Zoster Virus 
11 Bronchopneumonia 
10 Diarrhoea 10
32 No co-infection 
December 2013 (Supplement) East african MEdical Journal    S31
Table 4
Ultrasound features in the 79 patients with HIV and cholangiopathy/cholecystitis.
Anatomy/Event Number
Dilated intrahepatic and common bile duct 10
Isolated dilation of intrahepatic bile duct 8
Enlarged gall bladder with thickened wall, (cholecystitis) 31
Thickened common bile duct wall and cholecystitis 10
Cholecystitis and gall stones 11
Normal ultrasound 9
DISCUSSION
This series included 79 patients with AIDS-related 
cholangitis/cholangiopathy. The diagnosis was 
based on the four clinical signs; Jaundice, fever, 
diarrhoea and right upper quadrant abdominal pain 
and tenderness respectively, ultrasound findings 
and biochemical results. Thirty two (40.5%) patients 
had no co-morbidity while 47(59.5%) patients 
had co-infection or other morbidity (pulmonary 
tuberculosis, pneumocystis jiroveci pneumonia 
Cryptococcus meningitis, Kaposi’s sarcoma (skin, 
buccal), herpes zoster virus, chronic diarrhoea and 
cryptosporidium). The co-morbidities usually occur 
at low CD4+ cell counts, which was evident in these 
patients. Other studies have also demonstrated that 
HIV-related cholangiopathy complicates severe 
immuno-suppression. Patients are generally in poor 
condition and often have co-existing infections and 
or malignancies like Kaposi’s sarcoma and non 
Hodgkin’s lymphoma (15). 
 These patients had very low CD4+ cell counts, 
with a mean of 122.4± 85.8 cells/µl which signifies 
severe immuno-suppression. Research has shown that 
higher CD4+ cell and absolute lymphocyte counts and 
a shorter duration of HIV infection prior cholongitis 
are factors associated with better prognosis. The 
disturbance of liver function tests did not influence 
survival of patients (4, 5, 13, 14).
 Worse outcome measures are associated with 
high ALP levels, underlying immuno-suppression 
with a history of any opportunistic infections (9). 
HAART administration accounts for the recent 
dramatic improvement in survival of patients with 
AIDS cholangiopathy/cholangitis (9). Other major 
prognostic factors include CD4+ cell counts, duration 
of HIV sero-positivity and the patient's age (4, 5). In 
this cohort 47 patients had opportunistic infections 
and had poor prognosis and 32 patients had no 
opportunistic infection
 Ultrasound defines the morphological study 
and anatomy of the billiary system and even in 
advanced centres, is performed prior endoscopic 
retrograde cholangiopancreatography (ERCP) (4). 
In 2-3% of cases, ultrasound may miss gall bladder 
wall and bile duct thickening, which is demonstrable 
by computerised tomographic (C-T) scan (4). ERCP 
is both diagnostic and therapeutic and precisely 
defines the location of the billiary tree abnormality. 
In cases of papillary stenosis defined as a common 
bile duct dilatation of >10 mm, ERCP-guided 
endoscopic sphincterotomy can then be performed 
(4,13).  Sphincterotomy relieves pain and the patient’s 
quality of life improves. 
 ERCP is not available in our primary and 
secondary healthcare facilities and patients are 
managed conservatively. ECRP, if available allows 
for collection of bile for polymerase chain reaction 
(PCR) and micro-biological analysis for opportunistic 
infections (Cytomegalovirus, microsporidium, 
cryptosporidium and cyclospora), papillary biopsy 
if a tumour (primary or secondary) is suspected 
and endoscopic sphincterotomy. ECRP also enables 
dilatation of the papilla and insertion of a stent when 
indicated (6, 12).
 Bile duct dilatation and wall thickening 
on abdominal ultrasound are suggestive of 
cholangiopathy. Nevertheless, in this series, 
abdominal ultrasound was normal in nine(11%) 
patients. Ultra sound has low specifity for diagnosing 
ischaemic acalculuous cholecystitis, which may be 
due to HIV vasculitis (14).  
 Seven patients (8.9 %) had cholecystectomy done. 
They had choledocholithiasis, cholecystitis, sepsis 
and marked skin pruritus. They improved post-
operatively and were discharged. Eleven patients 
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(14%) had cholelithiasis and 68 patients (86%) had no 
cholelithiasis but abnormal liver function tests and 
right upper quadrant tenderness and are described as 
acalculous cholecystitis. This is usually suspected in 
HIV/AIDS patients presenting with vague abdominal 
pains and or diarrhoea with or without jaundice 
and fever. Causes of acalculous cholecystitis include 
cytomegalovirus (CMV), cryptosporidium, Kaposi’s 
sarcoma, mycobacterium avium intracellulare 
complex (MAC), isospora belli, pneumocystis jiroveci 
pneumonia and HIV itself (9,14,16-18). Suffice it to 
note that some studies have demonstrated multiple 
causes of acalculuous cholecystis, that is, CMV and 
cryptosporidium, and PJP and isospora belli (15). 
These infections are thought to cause ductal strictures 
in HIV/AIDS cholangiopathy (19, 20).
 Patients with HIV/AIDS with vague abdominal 
symptoms, right upper quadrant pain and 
tenderness should be evaluated for AIDS related 
cholangiopathy.
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